cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2017.9.10031cardio-33Research ArticleПРАКТИЧЕСКАЯ КАРДИОЛОГИЯ ПРИЛОЖЕНИЕ ДЛЯ ПРАКТИЧЕСКИХ ВРАЧЕЙ КЛИНИЧЕСКИЕ СЕМИНАРЫPRACTICAL CARDIOLOGY SUPPLEMENT FOR PRACTISING PHYSICIANS CLINICAL SEMINARSЛИЗИНОПРИЛ В ЛЕЧЕНИИ БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙLizinopril in the Treatment of Arterial HypertensionПодзолковВ. И.PodzolkovV. I.noemail@neicon.ruТарзимановаА. И.TarzimanovaA. I.tarzimanova@mail.ruФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава РФRussian Federation2017171120185797782Copyright © Kardiomag, 20182018KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/33

Несмотря на широкий выбор антигипертензивных препаратов, лишь небольшое число пациентов с артериальной гипертензией (АГ) лечатся эффективно. Ингибиторы ангиотензинпревращающего фермента (АПФ) рассматриваются как препараты первого выбора для стартовой терапии неосложненной АГ Среди множества представителей класса ингибиторов АПФ особого внимания заслуживает лизиноприл, который является одним из наиболее известных и хорошо изученных препаратов этой группы с широким спектром действия и доказанными органопротективными свойствами.

Despite availability of a wide selection of antihypertensive drugs, only a small portion of patients with arterial hypertension are treated effectively. Angiotensin converting enzyme inhibitors (ACEI) are considered drugs of first choice for starting therapy of uncomplicated arterial hypertension. Among large number of representatives of this class lisinopril deserves special attention as one of best known and well-studied ACEIs. Wide spectrum of activity and proven organoprotective qualities of lisinopril allow to use it a variety of situations.

артериальная гипертензиялечениелизиноприлarterial hypertensiontreatmentlisinoprilReferencesShalnova S.A., Konradi A.O., Karpov Yu.A. et al. Cardiovascular mortality in 12 Russian Federation regions - participants of the “Cardiovascular Disease epidemiology in Russian Regions" study Russ. J Cardiol 2012;5(97):6-11. Russian (Шальнова С.А., Конради А.О., Карпов Ю.А. и др. Анализ смертности от сердечно-сосудистых заболеваний в 12 регионах Российской Федерации, участвующих в исследовании «Эпидемиология сердечно-сосудистых заболеваний в различных регионах России». Российский кардиологический журнал 2012;5(97):6-11).Shalnova S.A., Konradi A.O., Karpov Yu.A. et al. Cardiovascular mortality in 12 Russian Federation regions - participants of the “Cardiovascular Disease epidemiology in Russian Regions" study Russ. J Cardiol 2012;5(97):6-11. Russian (Шальнова С.А., Конради А.О., Карпов Ю.А. и др. Анализ смертности от сердечно-сосудистых заболеваний в 12 регионах Российской Федерации, участвующих в исследовании «Эпидемиология сердечно-сосудистых заболеваний в различных регионах России». Российский кардиологический журнал 2012;5(97):6-11).Vasan R.S., Larson M.G., Leip E.P. et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001;358:1682-1686.Vasan R.S., Larson M.G., Leip E.P. et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001;358:1682-1686.ESH-ESC Guidelines Committee. 2013 ESH-ESC guidelines for the management of arterial hypertension. J Hypertension 2013;31:1281-1357. doi: 10.1097/01ESH-ESC Guidelines Committee. 2013 ESH-ESC guidelines for the management of arterial hypertension. J Hypertension 2013;31:1281-1357. doi: 10.1097/01Semple P.F. et al. Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man. Cardiovasc Drugs Ther 1987;1:45-50.Semple P.F. et al. Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man. Cardiovasc Drugs Ther 1987;1:45-50.Davis B.R., Culter J.A., Gordon D.J. Antihypertensive and lipidlowering treatment to prevent heart attack trial. Am J Hypertens 1996;9:342-60.Davis B.R., Culter J.A., Gordon D.J. Antihypertensive and lipidlowering treatment to prevent heart attack trial. Am J Hypertens 1996;9:342-60.Malacco E., Santonastaso M., Vari N.A. et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 2004;26(6):855-865.Malacco E., Santonastaso M., Vari N.A. et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 2004;26(6):855-865.Reisin E. Lisinopril versus HCTZ in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in obese Patients with Hypertension (TROPHY) Study Group. Hypertens 1997;30:140-145.Reisin E. Lisinopril versus HCTZ in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in obese Patients with Hypertension (TROPHY) Study Group. Hypertens 1997;30:140-145.Grimm R.H., Grandits G.A., Prineas R.J. et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygenic treatment in hypertensive men and women: treatment of mild hypertension study (TOMHS). Hypertension 1997;29:8-14.Grimm R.H., Grandits G.A., Prineas R.J. et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygenic treatment in hypertensive men and women: treatment of mild hypertension study (TOMHS). Hypertension 1997;29:8-14.Falkner B., Canessa M., Anzalone D. Effect of angiotensin converting enzyme inhibitor (lisinopril) on insulin sensitivity and sodium transport in mild hypertension. Am J Hypertens 1995;8(5 Pt.1):454-460.Falkner B., Canessa M., Anzalone D. Effect of angiotensin converting enzyme inhibitor (lisinopril) on insulin sensitivity and sodium transport in mild hypertension. Am J Hypertens 1995;8(5 Pt.1):454-460.Mancia G., Zanchetti A. et al. Study on monitoring of blood pressure and lisinopril evaluation. Circulation 1997;95(6);1464-1470.Mancia G., Zanchetti A. et al. Study on monitoring of blood pressure and lisinopril evaluation. Circulation 1997;95(6);1464-1470.Terpstra W.F., May J.F., Smit A.J.et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVE^A trial. J Hypertens 2001;19(2):303-309.Terpstra W.F., May J.F., Smit A.J.et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVE^A trial. J Hypertens 2001;19(2):303-309.Mogensen C.E., Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-1444.Mogensen C.E., Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-1444.Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997;349(9068):1787-1792.Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997;349(9068):1787-1792.Chazova I.E., Oshepkova E.V., Zhernakova Yu.V. et al. Diagnostics and treatment of arterial hypertension. Clinical guidelines. Cardiology Herald 2015;10(1):3-30. Russian (Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. и др. Клинические рекомендации. Диагностика и лечение артериальной гипертензии. Кардиологический вестник 2015;10(1):3-30).Chazova I.E., Oshepkova E.V., Zhernakova Yu.V. et al. Diagnostics and treatment of arterial hypertension. Clinical guidelines. Cardiology Herald 2015;10(1):3-30. Russian (Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. и др. Клинические рекомендации. Диагностика и лечение артериальной гипертензии. Кардиологический вестник 2015;10(1):3-30).Podzolkov V.I. Arterial hypertension. M: Medical news Agency 2016, р.424. Russian (Подзолков В.И. Артериальная гипертензия М: Медицинское информационное агентство, 2016, 424 с.),Podzolkov V.I. Arterial hypertension. M: Medical news Agency 2016, р.424. Russian (Подзолков В.И. Артериальная гипертензия М: Медицинское информационное агентство, 2016, 424 с.),GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-weekmortality and ventricular function after acutemyocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'InfartoMiocardico. Lancet 1994;343:1115-1122.GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-weekmortality and ventricular function after acutemyocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'InfartoMiocardico. Lancet 1994;343:1115-1122.Borghi C., Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: Results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003;145:80-87. DOI: 10.1067Borghi C., Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: Results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003;145:80-87. DOI: 10.1067Packer M., Poole-Wilson P.A., Armstrong P.W. et al. Comparative effects of low and high doses of the angiotensin-converting inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-2318.Packer M., Poole-Wilson P.A., Armstrong P.W. et al. Comparative effects of low and high doses of the angiotensin-converting inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-2318.

The authors declare that there are no conflicts of interest present.